Kim, Richard D., Harris, William P., Sung, Max W., Waldschmidt, Dirk Thomas, Cabrera, Roniel, Mueller, Udo, Menezes, Flavia, Ishida, Tatiane, Galle, Peter R. and El-Khoueiry, Anthony B. (2021). Results of a phase Ib study of regorafenib (REG) 80 mg/day plus pembrolizumab (PEMBRO) for first-line treatment of advanced hepatocellular carcinoma (HCC). J. Clin. Oncol., 39 (3). PHILADELPHIA: LIPPINCOTT WILLIAMS & WILKINS. ISSN 1527-7755

Full text not available from this repository.

Item Type: Journal Article
Creators:
CreatorsEmailORCIDORCID Put Code
Kim, Richard D.UNSPECIFIEDUNSPECIFIEDUNSPECIFIED
Harris, William P.UNSPECIFIEDUNSPECIFIEDUNSPECIFIED
Sung, Max W.UNSPECIFIEDUNSPECIFIEDUNSPECIFIED
Waldschmidt, Dirk ThomasUNSPECIFIEDUNSPECIFIEDUNSPECIFIED
Cabrera, RonielUNSPECIFIEDUNSPECIFIEDUNSPECIFIED
Mueller, UdoUNSPECIFIEDUNSPECIFIEDUNSPECIFIED
Menezes, FlaviaUNSPECIFIEDUNSPECIFIEDUNSPECIFIED
Ishida, TatianeUNSPECIFIEDUNSPECIFIEDUNSPECIFIED
Galle, Peter R.UNSPECIFIEDUNSPECIFIEDUNSPECIFIED
El-Khoueiry, Anthony B.UNSPECIFIEDUNSPECIFIEDUNSPECIFIED
URN: urn:nbn:de:hbz:38-599940
DOI: 10.1200/JCO.2021.39.3_suppl.323
Journal or Publication Title: J. Clin. Oncol.
Volume: 39
Number: 3
Date: 2021
Publisher: LIPPINCOTT WILLIAMS & WILKINS
Place of Publication: PHILADELPHIA
ISSN: 1527-7755
Language: English
Faculty: Unspecified
Divisions: Unspecified
Subjects: no entry
Uncontrolled Keywords:
KeywordsLanguage
OncologyMultiple languages
URI: http://kups.ub.uni-koeln.de/id/eprint/59994

Downloads

Downloads per month over past year

Altmetric

Export

Actions (login required)

View Item View Item